Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kite Pharma Inc.

Replenishing the cellular defenses of cancer patients

This article was originally published in Start Up

Executive Summary

Kite Pharma Inc.’s approach to cellular immunotherapy entails extracting T cells from patient blood, engineering them to recognize patients’ own tumor cells, and then reinfusing cells primed to go on the attack. While such ex vivo therapies have been tested for decades by expert clinicians with some success, Kite believes it will be the first to successfully commercialize them as options broadly available to cancer patients.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts